Solid Phase Peptide Synthesis: The Cycle Behind Research Peptides
Nearly every synthetic research peptide on a laboratory shelf was built the same way: one amino acid at a time, on a plastic bead, through a loop of chemical steps repeated for every residue in the chain. Solid phase peptide synthesis (SPPS) is the reason peptides can be made reliably at scale, and it is also the source of almost every impurity that later shows up on a certificate. For QC staff reading chromatograms and for procurement leads comparing lots, a working picture of the cycle makes those impurities, and the price differences between short and long sequences, much easier to understand.
Solid phase peptide synthesis: why use a bead?
The method was introduced by Bruce Merrifield in the 1960s, work later recognised with a Nobel Prize in Chemistry. Its central idea is to anchor the first amino acid to an insoluble resin bead and grow the chain from there.
Anchoring changes everything about purification. In ordinary solution chemistry, each intermediate must be isolated and cleaned before the next step. On a solid support, the growing chain stays attached to the bead, so excess reagents and by-products are simply washed away through a filter. A step that might take a day in solution becomes a rinse lasting minutes, which is what makes it practical to add dozens of residues in sequence and to automate the process.
The chain is built from the C-terminus towards the N-terminus, the reverse of the direction cells use. The choice of resin at the start also decides whether the finished peptide ends as a free acid or an amide, a point covered in our article on peptide terminal modifications.
One residue, one cycle
Most research peptides today are made with Fmoc chemistry, in which the amine of each incoming amino acid is temporarily protected by an Fmoc group and reactive side chains carry more permanent, acid-removable protection. Each residue is added through the same sequence:
- Fmoc removal. A base, most often piperidine in DMF, strips the Fmoc group from the end of the growing chain, leaving a free amine.
- Rinse. The resin is washed to remove the base and the released by-product.
- Activation and coupling. The next protected amino acid is activated, commonly with a carbodiimide plus an additive or with a uronium-type reagent, and forms a new amide bond with the free amine.
- Rinse. Excess activated amino acid and coupling by-products are washed out.
- Optional capping. Any chains that failed to couple can be acetylated so they stop growing.
Chemists can check progress along the way. A colour test for free amines shows whether a coupling has gone to completion, and the Fmoc by-product released at each deprotection absorbs UV light, which automated synthesisers can use to track each step.
The arithmetic of long sequences
No step is perfect, and the imperfections multiply. The share of chains that carry every intended residue is roughly the per-step efficiency raised to the power of the number of couplings:
| Per-coupling efficiency | 10 residues | 30 residues |
|---|---|---|
| 98% | about 82% | about 55% |
| 99% | about 90% | about 74% |
| 99.5% | about 95% | about 86% |
These figures are illustrative arithmetic, not measurements of any product. They show why a long sequence costs more to make well: it needs more cycles, more reagent, more purification effort, and it loses more material along the way.
How the cycle writes the impurity profile
Every class of synthesis impurity can be traced back to a particular step:
- Deletion sequences come from a coupling that did not finish. The chain carries on with one residue missing, giving a species that is very similar to the target and hard to separate from it.
- Truncated sequences come from chains that were capped or stopped growing. They are shorter, often acetylated, and usually easy to remove.
- Incompletely deprotected species keep a side-chain protecting group after cleavage and appear at a characteristic higher mass.
- Racemised residues, especially at cysteine and histidine, arise during activation and have the same mass as the target; our piece on racemisation and chiral purity covers them.
- Aspartimide-related products form at certain aspartate-containing motifs under the basic deprotection conditions.
Our article on deletion, truncation and oxidation impurities describes how each looks on a chromatogram and a mass spectrum.
From resin to vial
Once the last residue is in place, the peptide is released from the resin with trifluoroacetic acid, which at the same time removes the side-chain protecting groups. Scavengers are added to the cleavage mixture to trap the reactive fragments released by those groups before they can attach to sensitive residues. The crude peptide is usually precipitated, then purified by preparative reversed-phase HPLC and freeze-dried.
Because acid is present during cleavage and purification, the finished solid is commonly a trifluoroacetate salt unless a salt exchange is carried out. That counter-ion adds mass that is not peptide; see TFA and acetate counter-ions for what that means for weighing, and residual solvents for the other traces the process can leave.
What the synthesis route means for a volume buyer
For labs buying a compound in quantity, the synthesis route has a few practical consequences:
- Lot count matters. Each synthesis and purification run is its own lot, with its own impurity profile. Covering a large order from as few lots as possible keeps the material consistent.
- Impurity fingerprints are comparable. Lots made by the same route should show similar impurity peaks at similar relative retention. A new peak in a later lot is worth a question.
- Specifications should name the terminal form and salt. Both are set during synthesis and affect how the material weighs and behaves.
Bulk Peptides products are third-party tested by HPLC for purity, certificates are published for some products on the certificates of analysis page, and vials are matched to their certificate by cap and crimp colour. Mix-and-match pricing means every vial in a cart counts toward the volume break, which makes it straightforward to consolidate a multi-compound order.
This overview of synthesis chemistry is written for research and analytical readers. Bulk Peptides compounds are sold for in-vitro laboratory use only and are not for human or veterinary use.
